Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 17th June 2013
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Feline fibrosarcoma treatment to launch

New immunotherapeutic drug arriving in Autumn

It has been announced that the first immunotherapeutic cancer drug has been approved for veterinary use in Europe, and will launch in Autumn 2013.

The novel drug, Oncept IL-2, was unveiled by Merial R&D at a conference in Lisbon, as an innovative treatment for fibrosarcoma in cats.

A canarypox virus vector (ALVAC®) expressing Interleukin 2 (IL-2), has been selected for the treatment.

Hervé Poulet, R&D leader at Merial, explains: "It is very safe as it does not replicate and expresses IL-2 locally. It was found to be an efficacious adjunct treatment to surgery and radiotherapy."

During monocentric controlled trials of the drug, 71 cats with first occurrence fibrosarcoma were studied in three control groups.

One group received surgery and radiotherapy only, another also received low-dose IL-2 treatment, and the third received high-dose IL-2 alongside surgery and radiotherapy.

When treatment was given one day before the start of radiotherapy, it was found that the drug reduced the risk of relapse by 65 per cent compared to the control group, who received only surgery and radiotherapy.

Further, the median time for relapse rose from an average of 287 days to 730 days when the drug was administered, compared to when the drug was not used.

Presenting the results, Dr Dominique Jas of Merial R&D, said: "This study showed that the control group, that did not undergo immunotherapy, had poorer results than either treatment group – in spite of the cats receiving a total of thirty injections."

Merial's technical manager for companion animals, Catherine Pépin, added: “We’re very excited and proud to announce the forthcoming launch of a new immunotherapy, a recombinant canarypox virus expressing feline IL-2 at the site of injections."

Image from left: Pascal Fayard, Merial; Ana Lara, Royal Veterinary College; Herve Poulet, Merial R&D; Jolle Kirpensteijn, Utrecht University.

 

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.